leadf
logo-loader
viewShield Therapeutics PLC

Shield Therapeutics strongly supported for commercialisation, pricing of Feraccru after new data, says analyst

A licensing deal in the US, where it would be called Accrufer, can start to unlock the world’s largest iron replacement market

Shield Therapeutics PLC - Shield Therapeutics strongly supported for commercialisation, pricing of Feraccru after new data, says analyst

Shield Therapeutics PLC’s (LON:STX) fresh batch of data on Ferracru is strongly supportive of ongoing discussions for the global commercialisation, pricing and reimbursement, says Proactive analyst Emma Ulker.

Last week, the specialty pharmaceutical firm released findings of a reanalysis of the AEGIS-H2H study, indicating that its oral iron replacement treatment is a credible alternative to intravenous (IV) therapy for iron deficiency anaemia and corrects anaemia and maintains iron levels over the long term.

WATCH: Analysis of data from AEGIS-H2H is strongly supportive of ongoing discussions

Ulker said the long term clinical durability of Feraccru, its cost-efficacy and ease-of-use when compared to the standard IV iron, support discussions with potential US partners.

A licensing deal in the US, where it would be called Accrufer, can start to unlock the world’s largest iron replacement market which represents c70% of the estimated US$3bn global market.

The outcomes of the analysis can also help supporting STX’s partner Norgine to negotiate on pricing and coverage decisions in the broader European markets as well for ASK Pharm, the company’s partner in China, Ulker added.

See the report here.

Quick facts: Shield Therapeutics PLC

Price: 131.5 GBX

LSE:STX
Market: LSE
Market Cap: £154.1 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Market report: FTSE falters as US Federal Reserve decision takes centre stage

The FTSE 100 mixed this Wednesday after the (OECD) said the global economy is set to shrink 4.5% in 2020, which is not as bad as the 6% collapse it had forecast in June. Also today - the UK’s inflation fell to 0.2% in August, from 1% in July - due largely to the ‘Eat out to help out’ government...

1 week, 6 days ago

2 min read